BURLINGTON, Mass., May 14, 2014 /PRNewswire/ -- Decision Resources Group finds that the U.S. gynecological device market will recover to positive growth in 2016 after a several year decline. The decline is primarily a result of unfavorable clinical results that negatively affected the global endometrial ablation (GEA) and pelvic floor reconstruction (PFR) device markets. However, overall growth will begin to rebound in 2016, mainly due to the increase in the intrauterine device (IUD) market, but also owing to improvements in PFR device market growth and expansion of the assisted reproduction consumable (ARC) and hysteroscopic morcellator markets. Ultimately, the overall market will reach a value of nearly $1.3 billion by 2022.

Other key findings from the Medtech 360 report entitled US Markets for Gynecological Devices 2014:

  • GEA devices versus IUDs: The GEA device market will remain the largest segment of the U.S. gynecological device market until 2018, when it will be overtaken by IUDs. Since the Food and Drug Administration (FDA) approval of Bayer HealthCare's Mirena IUD in 2009, IUDs have increasingly become the first-line treatment for menorrhagia because they effectively regulate bleeding, preserve fertility, are entirely reversible and are less invasive than GEA devices.
  • PFR devices: The PFR device market will decline quickly over the next few years due to FDA warnings, hundreds of lawsuits and negative press coverage regarding serious complications associated with synthetic PFR mesh kits. However, this will gradually taper off and be resolved, allowing for market recovery.
  • Hysteroscopic morcellation versus resection: Hysteroscopic morcellators have enjoyed growing adoption over recent years as their clinical advantages over hysteroscopic resection are increasingly recognized; namely, hysteroscopic morcellators allow for a much simpler procedure and faster recovery times. However, hysteroscopic resection will remain more commonly performed through 2022 because of its longstanding history and lower cost relative to morcellation.
  • ARC devices: The ARC device market will benefit from rising demand for in vitro fertilization (IVF) as improvements to IVF technology result in higher success rates. As a result, more women are choosing IVF over artificial insemination.

Comments from Decision Resources Group Analyst Manya Aggarwal:

  • "Procedure volumes will be supported by the increasing number of gynecological procedures being performed in physician offices rather than hospitals, largely due to patients' shifting preferences toward less invasive procedures. The office environment is less intimidating for patients and also allows doctors to increase the volume of procedures they perform per day."
  • "Competitive dynamics will continue to shift in the gynecological device market as physicians opt for newer innovative devices. For example, companies that offer GEA devices, such as Hologic, Ethicon, Boston Scientific and CooperSurgical will suffer as Bayer HealthCare's IUD gains momentum. Similarly, female sterilization clip and band manufacturers such as CooperSurgical, Olympus and Richard Wolf will also have to contend with the growing popularity of Bayer HealthCare's Essure transcervical sterilization device."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Hospital Reimbursement Changes to Improve Market for Branded Drugs in Baltimore

View Now